Eone Diagnomics Genome Center Co., Ltd.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
As of 2026-10-09, Eone Diagnomics Genome Center Co., Ltd. has 8 Korean MFDS device approvals, 28 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2013 and listed on KOSDAQ in 2018, EDGC is a genomic big-data company established as a Korea-US joint venture between Korea's Eone Medical Foundation and US-based Diagnomics, Inc. It offers the non-invasive prenatal testing (NIPT) service NICE, the genetic ancestry analysis service YouWho, and the liquid biopsy cancer screening service OncoCatch, using Illumina's Global Screening Array (GSA)-based MGA chip. Health functional food product revenue accounted for 54.43% of sales in the prior fiscal year but fell to 0% in the most recent fiscal year.
Products & technology
- NICENon-invasive prenatal testing (NIPT)
- YouWhoDNA-based genetic ancestry analysis service
- OncoCatchLiquid biopsy-based early cancer detection
Regulatory approvals
data.go.kr8 Korean MFDS device approvals · 2016–2026
- MFDSExtractor, nucleic acid2026-03-24Product approval · Class 1체외 수신 26-628 호
- MFDSIVD reagents for cancer related gene2023-10-24Product approval · Class 3체외 제허 23-1000 호
- MFDSTube, blood collecting, sealed, evacuated2023-06-02Product approval · Class 1제신 23-883 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2022-03-28Product approval · Class 3체외 제허 22-209 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-12-09Product approval · Class 3체외 제허 21-996 호
- MFDSTube, blood collecting, sealed, evacuated2020-03-12Product approval · Class 1수신 20-641 호
- MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2017-07-31Product approval · Class 1제신 17-887 호
- MFDSTube, blood collecting, sealed, evacuatedRevoked2016-12-28Product approval · Class 1제신 16-1521 호
Key disclosures
KRX KIND via OpenDARTShow 21 more events
Publications
PubMed · affiliation-matched- Sex-specific accelerated epigenetic aging in the Alzheimer's disease spectrum.
Journal of Alzheimer's disease : JAD · 2026-05 · Park J, Kwon HJ, Joo J 외 4
- Machine Learning-Based Lung Cancer Classification Using Blood-Derived Microbial DNA: A Comparative Analysis of Taxonomic Profiling Strategies.
Diagnostics (Basel, Switzerland) · 2026-04 · Goh CJ, Park J, Kim Y 외 5
- EpiClock; biological age measurement from blood DNA methylation using a minimal CpG marker set for high-throughput iPlex mass spectrometry assay for screening in drug development and population health.
Experimental gerontology · 2025-11 · Kim H, Park AH, Kwon M 외 3
- Phosphatidic acid induces cytoskeletal rearrangements through the Src-FAK-RhoA/ROCK signaling pathway during decidualization.
The FEBS journal · 2025-09 · Jun HJ, Lee SY, Park SY 외 3
- Improving the accuracy of noninvasive prenatal testing through size-selection between fetal and maternal cfDNA.
Prenatal diagnosis · 2023-12 · Kwon HJ, Yun S, Joo J 외 4
- Improving CNV Detection Performance in Microarray Data Using a Machine Learning-Based Approach.
Diagnostics (Basel, Switzerland) · 2023-12 · Goh CJ, Kwon HJ, Kim Y 외 7
- Enhancing Lung Cancer Classification through Integration of Liquid Biopsy Multi-Omics Data with Machine Learning Techniques.
Cancers · 2023-09 · Kwon HJ, Park UH, Goh CJ 외 12
- Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer.
Scientific reports · 2023-08 · Kwon HJ, Shin SH, Kim HH 외 20
- Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma.
International journal of molecular sciences · 2023-04 · Chang HS, Kim Y, Lee SY 외 3
- PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models.
BMC medicine · 2023-02 · Park KC, Kim JM, Kim SY 외 8
Show 18 more publications
- Transferability of Alzheimer Disease Polygenic Risk Score Across Populations and Its Association With Alzheimer Disease-Related Phenotypes.
JAMA network open · 2022-12 · Jung SH, Kim HR, Chun MY 외 39
- House dust mite-induced Akt-ERK1/2-C/EBP beta pathway triggers CCL20-mediated inflammation and epithelial-mesenchymal transition for airway remodeling.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022-09 · Park SY, Kang MJ, Jin N 외 10
- Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test.
Diagnostics (Basel, Switzerland) · 2022-08 · Shim HW, Shin JH, Shin SC 외 11
- Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer.
International journal of molecular sciences · 2022-01 · Yun HJ, Kim M, Kim SY 외 5
- Dieckol induces cell cycle arrest by down-regulating CDK2/cyclin E in response to p21/p53 activation in human tracheal fibroblasts.
Cell biochemistry and function · 2022-01 · Heo SY, Jeong MS, Lee HS 외 4
- A Genome-Wide Association Study and Machine-Learning Algorithm Analysis on the Prediction of Facial Phenotypes by Genotypes in Korean Women.
Clinical, cosmetic and investigational dermatology · 2022-01 · Yoo HY, Lee KC, Woo JE 외 6
- Molecular diagnosis of McArdle disease using whole-exome sequencing.
Experimental and therapeutic medicine · 2021-09 · Kang JH, Park JH, Park JS 외 3
- Circulating tumor DNA in the saliva of patients with head and neck cancer: A pilot report.
Oral diseases · 2021-09 · Lee YC, Kim SI, Kwon H 외 2
- Correction to: Compound heterozygous variants including a novel copy number variation in a child with atypical ataxia-telangiectasia: a case report.
BMC medical genomics · 2021-09 · Lee HY, Jang DH, Kim JW 외 3
- Compound heterozygous variants including a novel copy number variation in a child with atypical ataxia-telangiectasia: a case report.
BMC medical genomics · 2021-08 · Lee HY, Jang DH, Kim JW 외 3
- Development of 50 InDel-based barcode system for genetic identification of tartary buckwheat resources.
PloS one · 2021-01 · Sohn HB, Kim SJ, Hong SY 외 6
- Phlorofucofuroeckol A from Ecklonia cava ameliorates TGF-β1-induced fibrotic response of human tracheal fibroblasts via the downregulation of MAPKs and SMAD 2/3 pathways inactivated TGF-β receptor.
Biochemical and biophysical research communications · 2020-02 · Heo SY, Jeong MS, Lee HS 외 3
- Hereditary Sensory and Autonomic Neuropathy 2B Caused by a Novel RETREG1 Mutation (c.765dupT) and Paternal Uniparental Isodisomy of Chromosome 5.
Frontiers in genetics · 2019-01 · Park GY, Jang DH, Lee DW 외 2
- Erratum: Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube.
Journal of gynecologic oncology · 2018-09 · Choi MC, Bae JS, Jung SG 외 8
- Differentiated Regional Homogeneity in Progressive Mild Cognitive Impairment: A Study With Post Hoc Label.
American journal of Alzheimer's disease and other dementias · 2018-09 · Cai S, Wang Y, Kang Y 외 6
- Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube.
Journal of gynecologic oncology · 2018-07 · Choi MC, Bae JS, Jung SG 외 8
- Comparison of Ion Personal Genome Machine Platforms for the Detection of Variants in BRCA1 and BRCA2.
Cancer research and treatment · 2018-01 · Hwang SM, Lee KC, Lee MS 외 1
- Integrated profiling of global metabolomic and transcriptomic responses to viral hemorrhagic septicemia virus infection in olive flounder.
Fish & shellfish immunology · 2017-12 · Cho SY, Kwon YK, Nam M 외 6
Patents
KIPRIS · applicant-matchedRegistered · 2025-09 · Application 1020250133162
Registered · 2025-08 · Application 1020250105533
Published · 2024-08 · Application 1020240102465
Published · 2024-01 · Application 1020240000236
PCT · Published · 2023-10 · Application PCT/KR2023/015423
PCT · Published · 2023-10 · Application PCT/KR2023/015425
PCT · Published · 2023-09 · Application PCT/KR2023/014409
Registered · 2023-07 · Application 1020230098982
Registered · 2023-06 · Application 1020230081465
Registered · 2023-06 · Application 1020230081467
Show 55 more patents
Registered · 2023-06 · Application 1020230079325
Registered · 2023-06 · Application 1020230079327
Registered · 2023-06 · Application 1020230079326
Published · 2023-03 · Application 1020230042531
Rejected · 2023-02 · Application 1020230020775
Registered · 2022-03 · Application 1020220026513
Registered · 2021-11 · Application 1020210158308
Registered · 2021-11 · Application 1020210158328
Registered · 2021-11 · Application 1020210158297
Registered · 2021-11 · Application 1020210158290
Registered · 2021-11 · Application 1020210158313
Rejected · 2021-10 · Application 1020210142120
Registered · 2021-07 · Application 1020210091905
PCT · Published · 2021-03 · Application PCT/KR2021/003531
Registered · 2021-03 · Application 1020210036799
US · Published · 2021-02 · Application 17436550
EP · Published · 2021-02 · Application 21757111.6
PCT · Published · 2021-02 · Application PCT/KR2021/002149
Registered · 2021-02 · Application 1020210021204
US · Published · 2020-12 · Application 17789117
EP · Published · 2020-12 · Application 20906126.6
PCT · Published · 2020-12 · Application PCT/KR2020/019070
US · Published · 2020-03 · Application 16833587
Registered · 2020-02 · Application 1020200022588
Registered · 2019-12 · Application 1020190175696
CN · Published · 2019-09 · Application 201980067323.3
PCT · Published · 2019-09 · Application PCT/KR2019/011527
Rejected · 2019-05 · Application 1020190064938
Registered · 2019-05 · Application 1020190063378
CN · Published · 2019-05 · Application 201910393850.5
Registered · 2018-09 · Application 1020180106466
Rejected · 2018-06 · Application 1020180068269
Rejected · 2018-06 · Application 1020180068268
Rejected · 2018-06 · Application 1020180068267
Rejected · 2018-06 · Application 1020180068266
Rejected · 2018-06 · Application 1020180068265
Rejected · 2018-06 · Application 1020180067094
Registered · 2018-03 · Application 1020180036911
Registered · 2018-02 · Application 1020180023766
Registered · 2017-09 · Application 1020170116049
US · Published · 2017-06 · Application 16312999
Registered · 2017-06 · Application 1020170072736
US · Published · 2017-01 · Application 16071537
CN · Published · 2016-08 · Application 201680051588.0
US · Registered · 2016-08 · Application 15750002
PCT · Published · 2016-08 · Application PCT/KR2016/008679
Withdrawn · 2016-03 · Application 1020160030258
Registered · 2016-01 · Application 1020160007181
Registered · 2015-08 · Application 1020150111221
CN · Published · 2015-06 · Application 201580079959.1
US · Published · 2015-06 · Application 15566484
EP · Published · 2015-06 · Application 15889288.5
PCT · Published · 2015-06 · Application PCT/KR2015/005905
Registered · 2015-04 · Application 1020150052649
Expired · 2014-05 · Application 1020140064009
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive8
- OpenAIOAI-SearchBot183
- GoogleGoogleOther38
- PerplexityPerplexityBot13
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 25, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Eone Diagnomics Genome Center Co., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.
Founded in 2002 and KOSDAQ-listed in 2013, Access Bio develops rapid diagnostic tests for malaria, COVID-19, and other infectious diseases.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
KOSDAQ-listed in-vitro diagnostics company selling PROTIA Allergy-Q allergy diagnostic products domestically and in 80+ countries.
Founded in 2000 and KOSDAQ-listed in 2013, i-SENS makes blood glucose monitors and point-of-care testing devices.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
Founded 2010, listed on KOSDAQ in 2021, Genesystem develops molecular diagnostic systems, biochips, test kits, and reaction reagents.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition